small molecule

ABILIFY MYCITE KIT

ARIPIPRAZOLE

Loss of exclusivityOctober 2033latest FDA-listed patent expiry
CompanyOtsuka PharmaceuticalView the full company profile on CliffBio

Drug detail

Brand nameABILIFY MYCITE KIT
Active ingredientARIPIPRAZOLE
Strength5MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2017
Marketing statusDISCN

Listed patents

PatentExpiresType
9268909October 2033product
10517507June 2032product
9320455December 2031product
11229378July 2031product
8547248December 2030product
8258962November 2030product
8961412November 2030product
9941931November 2030product
11464423September 2030product
8114021June 2030product
8545402April 2030product
8847766March 2030product
9149577December 2029product
8718193December 2029product
9433371September 2029product
8945005August 2029product
10441194July 2029product
8956288July 2029product
8674825April 2029product
9258035March 2029product
9060708March 2029product
9119554December 2028product
9444503November 2027product
8759350March 2027use U-1529
7978064September 2026product
9125939July 2026use U-1749
11476952April 2026product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ABILIFY MYCITE KIT patent cliff — loss of exclusivity October 2033 | CliffBio